The Growing Cannabidiol Market
The market for legal marijuana is growing at an ever-accelerating rate. Recent research by Arcview Market Research and BDS Analytics indicates that sales in North America reached almost $10 billion in 2017 and are expected to reach $24.5 billion by 2021 as more markets are created for both medical and recreational use. But this is still a sector threatened by great uncertainties and limitations. With no legal cannabis market in many parts of the globe, and with the current U.S. administration dominated by anti-marijuana conservatives, legal marijuana represents the troubled part of a larger CBD market.
For companies looking to that wider market, hemp offers a growing option for the CBD industry, one unfettered by many of the restrictions limiting marijuana. A report by the Brightfield Group shows that hemp is likely to become a billion-dollar market in the next three years. Used like cannabis in medicinal and nutritional products, it benefits from a high portion of online purchases – nearly two-thirds of hemp sales happen online.
Hemp also has the potential to reach larger international markets. The American-led war on drugs has encouraged an international climate that’s hostile to cannabis sales, but in which hemp products mostly remain legal.
Bringing Cannabidiol Products to China
One of the companies best set to make the most of this opportunity is ChineseInvestors (CIIX).
Founded in 1999, ChineseInvestors.com is a leading financial information website for Chinese-speaking investors in both the United States and China. Through its website, the company offers a range of investor information and services, including real-time market commentary, analysis and educational products. It also provides support services for companies looking to get into the Chinese market, including consulting for companies considering going public, advertising services and public relations-related support. With information in both English and Chinese language character sets, it provides an accessible presentation for investors looking at China both from the inside and the outside.
This is built around the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. In this way, CIIX helps investors make informed investment decisions and helps them meet their individualized financial goals. This includes a division committed to cryptocurrencies (http://nnw.fm/3pwZV), producing daily videos to inform Chinese investors about this ever-growing and unregulated sector of the Chinese economy.
Its position at the intersection of American and Chinese markets has put CIIX in a perfect position to explore the wider cannabidiol market. Marijuana use is illegal in China, but CBD oils, including hemp-based CBDs, are legal. CIIX is committed to developing and distributing hemp-based products in hopes of helping people improve their overall health, targeting epilepsy, Alzheimer’s disease, cirrhosis of the liver and various other health conditions. With nearly 10 million epilepsy patients in China, products that can help these customers have the potential to become big sellers in a growing market.
In December 2016, CIIX reached a wholesale agreement with a CBD health brand. Off the back of this, it launched its new subsidiary ChineseCBDoil.com. This website went live on Jan. 31, 2017, providing the world’s first Chinese language online store for CBD health products. It provides a variety of nutritional supplements containing CBD, including soft gels, capsules and concentrates available to Chinese-speaking customers worldwide.
Though the company has emphasized the health benefits of CBD products, it is also leveraging its financial and marketing expertise to sell hemp-infused skin care products in China.
Sales thus far have been so successful that the company is spinning off its subsidiary — CBD Biotechnology and ChineseHempOil.com, Inc. — with the intention of listing the new company’s common stock on the OTCQB (http://nnw.fm/Mxi3e). The site offers a variety of hemp oil products, including OptHemp Ultra Premium oil, peppermint-flavored hemp oil in softgels and gummies, and the Gold Plus line of premium hemp oil.
CIIX CEO Warren Wang expressed his confidence in this new development, stating in a press release, “We are excited to announce our intention to spin off CBD Biotechnology and ChineseHempOil.com, Inc. as we believe the existing business lines and the new acquisitions in China, secured by CEO Summer Yun, will allow these entities to continue to grow in their respective markets, while bringing new value to the Company’s existing shareholders.”
Growth and Challenges in America
The company’s hemp-based health products are available in the United States and Canada. Wang aims to double the company’s revenue and expand the business in 2018, with growth in North America as well as China. One of the tools to achieve this is a Yelp-style app for CBD customers. Approved for download by the Apple App Store, it is the world’s first Chinese-language mobile cannabis navigation application. The app carries an easily searchable database of marijuana dispensaries and cannabis strains. Customers can use the platform to review and discuss cannabis products, allowing them to find the best recommendations and nearby locations for medical and recreational cannabis. This will broaden the company’s reach and raise its profile in the growing number of states where marijuana is legally accessible.
CIIX is committed to further research into the use of hemp oil and other CBD products. The company in investing in research and design enterprises with the goal of developing CBD drugs to combat epilepsy and Alzheimer’s disease. The application period for new drugs of this type in China is two to four years, meaning that the company will be able to bring products to market far more quickly than in the United States. If this research pays off, then the company will not only be providing new uses for products in a growth sector of the economy, it will also be in position to launch them in the largest customer market in the world.
Because CBD remains classified as a Schedule 1 drug under the Controlled Substance Act administered in the United States by the Drug Enforcement Administration, hemp sales are regarded as illegal by the federal government despite the growing number of states legalizing it under their authority. Schedule 1 drugs are identified as substances with a high potential for abuse, no currently accepted medical use in the United States and a lack of safety protocols under medical supervision (http://nnw.fm/Nm4CO). This prohibition is being challenged in court, and that challenge now has the backing of a cross-party group of Congress members. The Congressional group’s arguments to the court state that the DEA’s ruling on CBD was an “abuse of DEA’s administrative procedure and rulemaking authority” and contrary to the definition of hemp set down by legislators in the 2014 Farm Bill (http://nnw.fm/Y2EPp). With such strong political support, the hemp industry is optimistic that this case will result in clarity and a lifting of the restrictions to permit easier expansion of CBD-based sales for companies such as CIIX.
The Cannabis Industry Connection
The deep connection between hemp production and the wider cannabis industry is shown by the work of companies such as Freedom Leaf (FRLF). A leading media producer and distributor in the cannabis and hemp industries, Freedom Leaf is a trusted source of information in the sector. The company is involved in mergers and acquisitions in the marijuana industry and has a portfolio of news, print and digital multi-media verticals, websites and web advertising, establishing it as a media outlet and discussion forum for a growing group of industries. It also provides services in branding, licensing and marketing these products, positioning it to make the most of fast growth in this sector.
One of the great pioneers of the cannabis sector in both North and South America, Medical Marijuana, Inc. (MJNA) is also involved in hemp. The first publicly traded cannabis company in the United States, the company also is situated in Brazil and Puerto Rico. This forward-looking company is exploring the medical and nutritional potential of hemp.
CV Sciences (CVSI) is both a researcher into CBD-based medicines and a producer of consumer food products based on that research. It is tapping into a wide range of market sectors through products such as its Purified Liquids products for vaping. Its PlusCBD Oil is the top-selling brand of hemp-derived CBD oil for consumers in the natural products industry.
On the agricultural side, Terra Tech (TRTC) is a vertically integrated, cannabis-focused company committed to cultivating and providing the highest quality medical cannabis. Its research-led approach to cultivating and cross-breeding marijuana strains leads to better products for treating a wide range of ailments. Its greenhouse and hydroponic systems allow the safe, efficient growth of cannabis and other plants in urban farming facilities, expanding the options for production in the CBD industry.
With the wider CBD industry growing, companies such as ChineseInvestors.com are aiming to profit from the growing power of hemp and its legal position in a disputed market.
For more information on ChineseInvestors.com, visit: ChineseInvestors.com (CIIX)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
No comments:
Post a Comment